China SXT Pharmaceuticals Inc

China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.

China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023

China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split

China SXT Pharmaceuticals (NASDAQ: SXTC ) stock is heading higher on Thursday even without any news from the pharmaceutical company. There's no recent news from China SXT Pharmaceuticals that explains today's rally.

Why Is China SXT Pharmaceuticals (SXTC) Stock Up 24% Today?

China SXT Pharmaceuticals (NASDAQ: SXTC ) stock is rocketing higher on Monday despite a lack of news from the pharmaceutical company. The Chinese pharmaceutical company hasn't released any new news or filings that explain today's rise.

Why Is China SXT Pharmaceuticals (SXTC) Stock Up 110% Today?

A 1-for-20 reverse split of the China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) stock has gone into effect. These are the details.

China SXT Pharmaceuticals (SXTC) Stock: 1-For-20 Reverse Split Goes Into Effect

TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that an 1 for 20 reverse split of its ordinary shares was approved by the Company's board of directors on May 10, 2022 and became effective on May 17, 2022. . In connection with the reverse share split, the Company's shareholders will receive one new ordinary share of the Company for every twenty shares they hold. The Company's ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on May 19, 2022,

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

CYREN

Petros Pharmaceuticals

Are these strategies on your list for buying penny stocks next month? The post Best Penny Stocks, How To Buy & Strategies for Beginners appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks, How To Buy & Strategies for Beginners

SXTC stock is soaring higher on no company-specific news. Positive developments between the U.S. and China may be fueling gains.

Why Is China SXT Pharmaceuticals (SXTC) Stock Up Today?

Guardforce AI Co Ltd

Hycroft Mining Holding Corporation

Here's what you need to know about trading penny stocks on March 29th The post Trading Penny Stocks? Top Stock Market News for March 29th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 29th, 2022

Leju Holdings Ltd.

Secoo Hld

TherapeuticsMD

Penny Stocks Under $1 To Watch This Week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Explosive Stocks Under $1 To Watch Now

AnPac Bio-Medical Science Co

Canaan Inc.

iQIYI

Meten Holding Group Ltd.

China penny stocks to watch right now The post Best Penny Stocks To Buy? 5 China Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 5 China Stocks To Watch Right Now

TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it entered into a securities purchase agreement to issue  a convertible promissory note in the original principal amount of $2,804,848.00 to Streeterville Capital, LLC, a Utah limited liability company.

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million

NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC). About China SXT Pharmaceuticals, Inc. Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).

TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the closing of an underwritten public offering (the “Offering”) of its ordinary shares and prefunded warrants to purchase ordinary shares, and the simultaneous closing of the overallotment option, with gross proceeds to the Company to be approximately $4.1 million, assuming the pre-funded warrants will be fully exercised and before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The Offering equates to 22,777,774 of the Company's ordinary shares. The ordinary shares are offered at a price of $0.18 per share and the pre-funded warrants are offered at the same price per share as the ordinary shares, less the $0.01 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this Offering for general corporate purposes, including, but not limited to, working capital and other business opportunities.

China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment

TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the pricing of an underwritten public offering of its ordinary shares and prefunded warrants to purchase ordinary shares, with gross proceeds to the Company expected to be approximately $3.5 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The Offering equates to 19,806,760 of the Company's ordinary shares at a price of $0.18 per share. The pre-funded warrants are offered at the same price per share as the ordinary shares, less the $0.01 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities.

China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) fell by over 45% pre-market today. This is why it happened.

China SXT Pharmaceuticals Stock (SXTC): Why The Price Substantially Went Down Today

TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it intends to offer in an underwritten public offering its ordinary shares and prefunded warrants to purchase ordinary shares. The pre-funded warrants shall be offered at the same price per share as the ordinary shares, less the $0.0001 per share exercise price of each pre-funded warrant. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The base offering is expected to be up to approximately $3.4 million, and the underwriter will receive an overallotment option to purchase an additional 15% of the number of ordinary shares and/or pre-funded warrants sold for 45 days following the closing.

China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that it develops and commercializes the Kuihuapan After-Soaking-Oral TCMP and Zhudanfen Directly-Oral TCMP products. The Kuihuapan products are produced according to the four processing specifications of Chinese Pharmacopoeia (2020 Edition) No.

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

TAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that it recently received a new Pharmaceutical Manufacturing Permit ("PMP") from Jiangsu Province Medical Products Administration (JSMPA) with a new production scope of lyophilization processing. The Company also passed its pharmaceutical GMP compliance-inspection conducted by JSMPA for the Company's new lyophilization production facility.

China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection

The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) increased by over 40% during intraday trading. These are some details you should know.

SXTC Stock Increases Over 40% Intraday: Details You Should Know

Aehr Test Systems

TD Holdings Inc

TDH Hlds

These 3 Penny Stocks to Watch Pushed Up Substantially Today; Worth it or Not? The post 4 ‘High Volume' Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 ‘High Volume' Penny Stocks to Watch in July 2021

The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) has increased by over 20% pre-market. This is why it happened.

SXTC Stock Price Increased Over 20% Pre-Market: Why It Happened

The stock price of China SXT Pharmaceuticals (NASDAQ: SXTC) is trading at over 200% pre-market. This is why it happened.

SXTC Stock Price Increases Over 200% Pre-Market: Why It Happened

TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"),...

News for China SXT Pharmaceuticals Inc Stock (SXTC)